Impact of Xpert MTB/RIF on antiretroviral therapy-associated tuberculosis and mortality: A pragmatic randomized controlled trial

Open Forum Infectious Diseases

Volumn 1, Issue 1, 2014, Pages

  Mupfumi, L ^a,b   Makamure, B ^a,b   Chirehwa, M ^b   Sagonda, T ^b   Zinyowera, S ^c   Mason, P ^a,b   Metcalfe, J Z ^d   Mutetwa, R ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b Biomedical Research and Training Institute   (Zimbabwe)

^c National Microbiology Reference Laboratory   (Zimbabwe)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ART associated TB; GeneXpert MTB RIF; HIV; Screening; Tuberculosis

Indexed keywords

EFAVIRENZ; ISONIAZID; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; FLUORESCENCE MICROSCOPY; FOLLOW UP; GENE SEQUENCE; GENETIC SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MORTALITY RATE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RAPID TEST; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS; ZIMBABWE;

EID: 84926305915     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu038     Document Type: Article

References (43)

1. UN Joint Programme on HIV/AIDS, Treatment 2015, July 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2484_treatment-2015_en.pdf. Accessed 13 August 2013.
2. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-908.
3. Kranzer K, Houben RM, Glynn JR, et al. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:93-102.
4. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:570-81.
5. FIND. WHO monitoring of Xpert MTB/RIF roll-out. Available at: http://www.stoptb.org/wg/gli/assets/documents/map/1/atlas.html. Accessed 20 August 2013.
6. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
7. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
8. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. New Engl J Med 1980; 302:1109-17.
9. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-25.
10. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13:349-61.
11. Neumann PJ, Tunis SR. Medicare and medical technology-the growing demand for relevant outcomes. New Engl J Med 2010; 362:377-9.
12. Bratton DJ, Nunn AJ. Alternative approaches to tuberculosis treatment evaluation: the role of pragmatic trials. Int J Tuberc Lung Dis 2011; 15:440-6.
13. Mupfumi L, Mason P, Zinyowera S, Mtetwa R. The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare. In: XIX International AIDS Conference. Washington DC, 2012.
14. National TB Program. Zimbabwe National TB Guidelines. 4th ed, 2010:116.
15. Rangaka MX, Wilkinson RJ. Isoniazid prevention of HIV-associated tuberculosis. Lancet Infect Dis 2013; 13:825-7.
16. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516-23.
17. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-9.
18. Gupta A, Wood R, Kaplan R, et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PloS One 2013; 8: e55824.
19. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-93.
20. Lawn SD, KerkhoffAD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071-9.
21. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-8.
22. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 (Suppl 1): 1-15.
23. Xpert MTB/RIF vs microscopy as the first line TB test in South Africa: mortality, yield, initial loss to follow up and proportion treated. The XTEND study. Available at: http://www.stoptb.org/wg/gli/assets/documents/M6/Churchyard%20-%20XTEND%20study.pdf. Accessed 21 May 2014.
24. Treatment Action Group. Tuberculosis Research and Development: 2013 Report on Tuberculosis Research Funding Trends, 2005-2012. November 2013. Available at: http://www.treatmentactiongroup.org/sites/g/files/g450272/f/201310/TAG_TB_2013_8.5.pdf. Accessed 20 May 2014.
25. Trebucq A, Enarson DA, Chiang CY, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15:1567-72.
26. Singh JA, Bhan A. The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert (R) MTB/RIF. Int J Tuberc Lung Dis 2011; 15:1563.
27. Dowdy DW, Davis JL, den Boon S, et al. Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa. PloS One 2013; 8:e70485.
28. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2013; 383:424-35.
29. Yoon C, Cattamanchi A, Davis JL, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PloS One 2012; 7:e48599.
30. Theron G, Peter J, Dowdy D, et al. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 2014; doi:10.1016/S1473-3099(13)70360-8.
31. Zar HJ, Workman L, Isaacs W, et al. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. Lancet Glob Health 2013; 1:e97-104.
32. Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PloS One 2013; 8:e65421.
33. Steingart KR, Schiller I, Horne DJ, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database System Rev 2014; 1:CD009593.
34. REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment. AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases. Available at: http://clinicaltrials.gov/show/NCT01380080%20. Accessed 26 November 2013.
35. Luoto J, Maglione MA, Johnsen B, et al. A comparison of frameworks evaluating evidence for global health interventions. PLoS Med 2013; 10: e1001469.
36. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a costeffectiveness analysis. PLoS Med 2011; 8:e1001120.
37. Andrews JR, Lawn SD, Dowdy DW, Walensky RP. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis 2013; 57:1021-6.
38. Zimbabwe Health System Assessment. USAID. 2010 Available at: http://www.healthsystems2020.org/content/resource/detail/2812/. Accessed 25 November 2013.
39. Lim E, Brown A, Helmy A, et al. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med 2008; 149: 612-7.
40. Greenland S. Nonsignificance plus high power does not imply support for the null over the alternative. Ann Epidemiol 2012; 22:364-8.
41. Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem 2012; 58:1636-43.
42. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42:252-71.
43. Denkinger CM, Nicolau I, Ramsay A, et al. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J 2013; 42:544-7.